Gilde Healthcare

Gilde Healthcare (LSI Europe ‘25 Investor) is a specialized healthcare investor managing over $2.6 billion across two fund strategies: Venture&Growth and Private Equity. The firm is headquartered in Utrecht, Netherlands, with offices also in Frankfurt, Germany, and Boston, USA. In November of 2023, Gilde Healthcare announced the final close of its Gilde Healthcare Venture&Growth VI fund with €740 million in commitments. Fund VI reached the hard cap following a first close at €600 million in April 2023. The latest fund focuses on fast-growing companies developing solutions for better care at lower cost. Gilde Healthcare invests in companies in Europe and North America active in digital healthcare, Medtech, and therapeutics. The new fund will invest €10-70 million per new portfolio company. The Venture&Growth fund portfolio includes companies like: • Argá Medtech SA (David Neale) • GT Medical Technologies, Inc. (Per Langoe) • Mainstay Medical (Jason Hannon) • Volta Medical (Théophile Mohr Durdez) Join us in welcoming General Partner Janke Dittmer, Investment Managers Henry Zubaida and Susana Amorim Lopes, and Associate Christopher Allen to LSI Europe ‘25, taking place September 7–11 in London. Want to join us at LSI Europe ‘25? Price increases on August 1st. Register on our website today for your opportunity to connect with the industry's top decision-makers at LSI Europe ‘25 on September 7-11 in London.

https://lnkd.in/euvikRzZ Gilde Healthcare is excited that its portfolio company Purespring Therapeutics is one step closer to demonstrating that PS-002 can target the underlying cause of patients suffering from primary IgA nephropathy (IgAN). IgAN is a chronic autoimmune kidney disease that primarily affects young adults. PS-002 is the first to modulate complement activation in the kidney via precision targeting of podocytes. The approval enables to start clinical trials in patients with primary IgA nephropathy.   #LifeSciences #Biotech #GildeHealthCare #nephrology #phase1 #IND   Arthur Franken Sonia Hallen Marion Pouillard

https://lnkd.in/eZYgnFVt Gilde Healthcare announces the combined investments in Artinis Medical Systems and NIRx Medical Technologies, both pioneers in functional Near-Infrared Spectroscopy (fNIRS) solutions. This dual transaction brings together two highly complementary companies, establishing a new global leader in fNIRS. We look forward to work together with the combined management team to fuel ground-breaking neuroscience research.   Thanks to all that made this complex transaction possible: Greenberg Traurig, LLP, RSM, DeciBio, Zuidbroek Ondernemingsrecht Notarissen, Deloitte, Clifford Chance, DLA Piper, Thompson LLP, England & Company, JPR advocaten and Moore MKW. With special thanks to both founder/management teams for their trust in this project: Randall Barbour, Richard Barbour, Patrick Britz PhD, Mylene Dr. Henry, Willy Colier, Roeland van der Burght and Marianne Floor-Westerdijk. Boyd Rutten, Stephan Wachtveitl, Jelte Goettsch, Mette Stapel, Ludo Suykerbuyk, Oksana van Vliet (Vynarchyk) and support of Olivier Heyning.

🌍🚴♂️ On June 20, members of the Gilde Healthcare team proudly took part in Cycling 4 Climate - a powerful initiative raising awareness for the urgent need to accelerate climate action. At Gilde Healthcare, we are committed to supporting the transition to a more sustainable future - both through personal action and investing. With our VC and PE fund strategies we are actively investing in impactful companies providing solutions for patients and our planet! Kudos to our colleagues who took on the ride and showed that climate commitment starts with action. 💪🌱 #Cycling4Climate #ClimateSolutions #PrivateEquity #ImpactInvesting #GildeHealthcare #EnergyTransition Pieter van der Meer David de Graaf Silke Kranz Stacey Vrijhof Pommeline Korstanje Harriët Katsman Katharina Mono Tristan Maguet Christopher Allen Kevin Feenstra

🎉 We’re proud to share that Gilde Healthcare has been named a finalist for the Real Deals Impact Investor of the Year – Social at the Sustainable Investment Awards 2025!   This recognition highlights our continued commitment to driving meaningful impact through our investments in healthcare innovation and climate solutions. Investing in solutions for tomorrow's world!    #ImpactInvesting #HealthcareInnovation #ClimateSolutions #SIA25 #GildeHealthcare #PrivateEquity 

🎉 We’re proud to share that Gilde Healthcare has been named a finalist for the Real Deals Impact Investor of the Year – Social at the Sustainable Investment Awards 2025!   This recognition highlights our continued commitment to driving meaningful impact through our investments in healthcare innovation and climate solutions. Investing in solutions for tomorrow's world!    #ImpactInvesting #HealthcareInnovation #ClimateSolutions #SIA25 #GildeHealthcare #PrivateEquity 

We are proud to announce the new name of our portfolio company Scharenborg Groep: Stepp Footcare. A name that fits with their concept of Total Footcare and its integrated disciplines: podiatry, orthopedic shoe technology, pedicure, stores and manufacturing. On to the next Stepp!

Ben jij sustainability/climate consultant met ervaring met opstellen van environmental impact assessments, berekenen van carbon footprinting (scope 1,2 & 3) en opstellen van LCA’s? Check dan deze climate specialist vacature in investment bij Gilde Healthcare in Utrecht!

Congratulations to Gilde Healthcare company Volta Medical on the first U.S. label with level one evidence for persistent AF. Ariane Daney de Marcillac Christopher Allen Edward Hanlon Edwin de Graaf Geoff Pardo Henry Zubaida Janke Dittmer Karthik Bolisetty Pieter van der Meer Richard Wilmot Susana Amorim Lopes

https://lnkd.in/eTUQuDqG We are pleased to announce that Gilde Healthcare company SpliceBio has raised a $135M in Series B financing. Besides significant contributions from Gilde Healthcare and other existing investors, the round was co-led by EQT Life Science and Sanofi Ventures with participation from Roche Venture Fund. This brings SpliceBio a significant step closer towards a therapy for patients suffering from Stargardt disease and enables to expand its pipeline of Genetic Medicines. Join us in congratulating the fantastic team at SpliceBio with this important milestone towards their mission to develop treatments for patients suffering from severe inherited retinal diseases.   #Gilde #SpliceBio #LifeSciences #Biotech #Stargardt #RareDisease   Arthur Franken Edwin de Graaf Henry Zubaida Iskander Shadid Joep Muijrers Marion Pouillard Pieter van der Meer Stefan Luzi, PhD Tristan Maguet Zosia van Eesteren Besmire Ahmati Jan Willem Bakker